26
|
Mok T, Peters S, Camidge DR, Gadgeel S, Ou S, Kim D, Dziadziuszko R, De Marinis F, Sangha R, Zeaiter A, Noe J, Nueesch E, Liu T, Loftin I, Williams C, Shaw A. JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.314] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Garassino M, Cortesi E, Grossi F, Chiari R, Parra HS, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Gamucci T, Ceresoli G, Antonelli P, Vasile E, Pinto C, Galetta D, Macerelli M, De Marinis F. MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.550] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Wolf J, Han J, Nishio M, Souquet P, Paz-Ares L, De Marinis F, Seto T, De Jonge M, Kim T, Vansteenkiste J, Tan D, Garon E, Groen H, Hochmair M, Felip E, Reguart N, Thomas M, Overbeck T, Ohashi K, Giovannini M, Yura R, Joshi A, Akimov M, Heist R. PS04.06 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.075] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, De Marinis F, Minuti G, Buosi R, Morabito A, Spitaleri G, Gridelli C, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Alì G, Proietti A, Fontanini G, Joseph A, Crinò L, Cappuzzo F. P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Passaro A, Metro G, Tiseo M, Migliorino M, Santo A, Sperandi F, Maione P, Puppo G, Grossi F, Soto Parra H, Borra G, Roca E, Rocco D, Stasi I, Galetta D, Carta A, Milella M, Fasola G, Gebbia V, Ferrari S, De Marinis F. ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Grossi F, Crinò L, Delmonte A, Turci D, Lo Russo G, De Marinis F, Soto Parra H, Galetta D, Cappuzzo F, Sperandi F, Tiseo M, Puppo G, Roila F, Migliorino M, Tonini G, Cognetti F, Santoro A, Tassinari D, Scoppola A, Cortesi E. Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Crinò L, Bidoli P, Roila F, Cortesi E, Garassino M, Cappuzzo F, Grossi F, Tonini G, Sarobba G, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Alfonso I, De Marinis F, Delmonte A. Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Garassino M, Cortesi E, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Gamucci T, Ceresoli G, Antonelli P, Vasile E, Pagano M, Macerelli M, Lagroscino A, De Marinis F. Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
De Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Schuler M, Yang JCH, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016; 27:417-23. [PMID: 26646759 PMCID: PMC4769992 DOI: 10.1093/annonc/mdv597] [Citation(s) in RCA: 108] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Revised: 11/11/2015] [Accepted: 11/23/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy. PATIENTS AND METHODS Patients with relapsed/refractory disease following ≥1 line of chemotherapy, and whose tumors had progressed following initial disease control (≥12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m(2)/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes. RESULTS Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent. CONCLUSION Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy. TRIAL REGISTRATION NUMBER NCT01085136 (clinicaltrials.gov).
Collapse
|
36
|
Schuler M, Planchard D, Yang JC, De Marinis F, Bennouna J, Kim JH, Chouaid C, Wiewrodt R, Grossi F, Feng J, Strausz J, Lu S, Kim DW, Liu X, Chen YM, Zhou C, Wang B, Chand VK, Park K. Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and A: LUX-Lung 5 (LL5). Pneumologie 2015. [DOI: 10.1055/s-0035-1544761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Casiraghi M, Solli P, De Marinis F, Petrella F, Guarize J, Spaggiari L. 157-I * SALVAGE SURGERY AFTER DEFINITIVE CHEMORADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu276.157] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Middleton G, Gridelli C, De Marinis F, Pujol J, Reck M, Ramlau R, Parente M, Pieters T, Visseren-Grul C, Antonio BS, John W, Zimmermann A, Chouaki N, Paz-Ares L. Evaluation of Changes in Renal Function in a Phase III Study of Maintenance (Mtc) Pemetrexed (Pem) Plus Best Supportive Care (Bsc) Versus Placebo (Plb) Plus Bsc After Induction Treatment (Tx) with Pem Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer (Paramount). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.36] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Planchard D, Park K, Yang J, Kim J, De Marinis F, Chen Y, Feng J, Chouaid C, Lu S, Wiewrodt R, Zhou C, Bennouna J, Liu X, Lungershausen J, Wang B, Chand V, Schuler M. Patient-Reported Outcomes (Pros) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) Receiving Afatinib (A) Monotherapy Followed By a + Paclitaxel (A + P) Vs Investigator'S Choice of Single-Agent Chemotherapy (Ic): Lux-Lung 5 (Ll5). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.44] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Park K, Kim J, Schuler M, Planchard D, De Marinis F, Chen Y, Zhou C, Bennouna J, Xiaoqing L, Feng J, Bidoli P, Strausz J, Chouaid C, Huang M, Ho L, Wang B, Chand V, Yang J. Afatinib (A) Followed By a + Paclitaxel (P) or Investigator'S Choice of Single-Agent Chemotherapy (Ic) in Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung: Subgroup Analysis of Lux-Lung 5 (Ll5). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.42] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G, Della-Fiorentina S, Begbie S, Jennens R, Dass J, Pittman K, Ivanova N, Koynova T, Petrov P, Tomova A, Tzekova V, Couture F, Hirsh V, Burkes R, Sangha R, Ambrus M, Janaskova T, Musil J, Novotny J, Zatloukal P, Jakesova J, Klenha K, Roubec J, Vanasek J, Fayette J, Barlesi F, Bennouna-Louridi J, Chouaid C, Mazières J, Vallerand H, Robinet G, Souquet PJ, Spaeth D, Schott R, Lena H, Martinet Y, El Kouri C, Baize N, Scherpereel A, Molinier O, Fuchs F, Josten K, Manegold C, Marschner N, Schneller F, Overbeck T, Thomas M, von Pawel J, Reck M, Schuette W, Hagen V, Schneider CP, Georgoulias V, Varthalitis I, Zarogoulidis K, Syrigos K, Papandreou C, Bocskei C, Csanky E, Juhasz E, Losonczy G, Mark Z, Molnar I, Papai-Szekely Z, Tehenes S, Vinkler I, Almel S, Bakshi A, Bondarde S, Maru A, Pathak A, Pedapenki R, Prasad K, Prasad S, Kilara N, Gorijavolu D, Deshmukh C, John S, Sharma L, Amoroso D, Bajetta E, Bidoli P, Bonetti A, De Marinis F, Maio M, Passalacqua R, Cascinu S, Bearz A, Bitina M, Brize A, Purkalne G, Skrodele M, Baba A, Ratnavelu K, Saw M, Samson-Fernando M, Ladrera G, Jassem J, Koralewski P, Serwatowski P, Krzakowski M, Cebotaru C, Filip D, Ganea-Motan D, Ianuli C, Manolescu I, Udrea A, Burdaeva O, Byakhov M, Filippov A, Lazarev S, Mosin I, Orlov S, Udovitsa D, Khorinko A, Protsenko S, Chang A, Lim H, Tan Y, Tan E, Bastus Piulats R, Garcia-Foncillas J, Valdivia J, de Castro J, Domine Gomez M, Kim S, Lee JS, Kim H, Lee J, Shin S, Kim DW, Kim YC, Park K, Chang CS, Chang GC, Goan YG, Su WC, Tsai CM, Kuo HP, Benekli M, Demir G, Gokmen E, Sevinc A, Crawford J, Giaccone G, Haigentz M, Owonikoko T, Agarwal M, Pandit S, Araujo R, Vrindavanam N, Bonomi P, Berg A, Wade J, Bloom R, Amin B, Camidge R, Hill D, Rarick M, Flynn P, Klein L, Lo Russo K, Neubauer M, Richards P, Ruxer R, Savin M, Weckstein D, Rosenberg R, Whittaker T, Richards D, Berry W, Ottensmeier C, Dangoor A, Steele N, Summers Y, Rankin E, Rowley K, Giridharan S, Kristeleit H, Humber C, Taylor P. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24:2875-80. [DOI: 10.1093/annonc/mdt371] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Obasaju C, Paz-Ares L, De Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O, Sahoo T, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann A, Visseren-Grul C, Gridelli C. Maintenance Pemetrexed (PEM) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC after PEM Plus Cisplatin for Advanced Nonsquamous NSCLC. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)31933-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
43
|
Reck M, Paz-Ares L, De Marinis F, Molinier O, Prasad Sahoo T, Laack E, John W, Zimmermann A, Visseren-Grul C, Gridelli C. Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33787-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
44
|
Rosell R, Sureda BM, Costa C, Molina M, Gimenez-Capitan A, Karachaliou N, Wei J, Vergnenegre A, Giannikopoulos P, Mermel C, Bivona T, De Marinis F, Felip E, Bueno TM, Gervais R, Santarpia M, Majem M, Bosch-Barrera J, Garcia-Campelo M, Paz-Ares L. Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34341-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
45
|
Gori B, Del Signore E, Fulvi A, Ricciardi S, Migliorino M, Belli R, Condò S, De Santis S, Colacchi A, De Marinis F. Erlotinib Role in Pretreated Egfr Wild Type Caucasian Patients: A Retrospective Observational Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33808-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
46
|
De Marinis F, Rosell R, Vergnenegre A, Massuti B, Felip E, Gervais R, Cardenal F, Garcia-Gomez R, Taron M, Paz-Ares L. 9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72328-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Caffo O, Ceribelli A, De Marinis F, Bulotta A, Novello S, Bearz A, Durante E, Grossi F, Pegoraro M, Tiseo M. 9147 POSTER Treatment and Clinical Outcomes of Young Patients (^40 Years) With Advanced Non-small Cell Lung (NSCLC) – Data From a Retrospective Multicentric Database. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72459-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
48
|
Paz-Ares LG, De Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed SA, John WJ, Chouaki N, Zimmerman A, Visseren Grul CM, Gridelli C. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.cra7510] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA7510 Background: The PARAMOUNT trial investigated whether pem continuation maintenance therapy improves progression-free survival (PFS) after pem-cisplatin induction therapy in patients (pts) with advanced nonsquamous NSCLC. Methods: In this double-blind, placebo-controlled trial, 939 pts participated in the induction phase, specified as four cycles of induction pem (500 mg/m2) and cisplatin (75 mg/m2) on day 1 of a 21-day cycle. Pts who had not progressed during pem-cisplatin induction and had an Eastern Cooperative Oncology Group performance status (PS) of 0/1 (n=539; 57.4%) were randomized (2:1, stratified for disease stage, PS, and induction response) to maintenance pem (500 mg/m2 on day 1 of a 21-day cycle) plus BSC (n=359) or placebo plus BSC (n=180) until disease progression. All pts received vitamin B12, folic acid, and dexamethasone. The primary endpoint was PFS (target: HR=0.65, two-sided alpha=0.05; 90% power with minimum of 238 events). Results: Pt characteristics were balanced between arms: median age=61 years; 58% male; 95% Caucasian; 32% PS 0; 91% stage IV; 87% adenocarcinoma; and 45% induction complete/partial response. Pem continuation maintenance resulted in a 36% reduction in the risk of progression (HR=0.64, 95% CI: 0.51-0.81; P=0.00025). The median independently reviewed PFS (472 pts, 297 events), measured from randomization, was 3.9 months (95% CI: 3.0-4.2) on the pem arm, and 2.6 months (95% CI: 2.2-2.9) on the placebo arm. The disease control rate (% pts with response/stable disease) was 71.8% on the pem arm, and 59.6% on the placebo arm (P=0.009). The drug-related serious adverse event (AE) rate was 8.9% on the pem arm, and 9.2% of pts had grade 3/4 laboratory Common Toxicity Criteria AEs. On the placebo arm, the rates were 2.8% and 0.6%, respectively. Discontinuations due to AEs were 5.3% on the pem arm, 3.3% on the placebo arm. Conclusions: PARAMOUNT met its primary endpoint and showed that pem continuation maintenance following pem-cisplatin induction is an effective and well tolerated treatment for pts with advanced nonsquamous NSCLC.
Collapse
|
49
|
Ardizzoni A, Boni L, Tiseo M, Vincent A, Passalacqua R, Camerini A, Labianca R, Genestreti G, Zanelli F, Ciuffreda L, Di Costanzo F, De Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Smit EF. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Paz-Ares LG, De Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed SA, John WJ, Chouaki N, Zimmerman A, Visseren Grul CM, Gridelli C. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.cra7510] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|